Abstract:Berberine hydrochloride (BBR), used in various traditional medicinal practices, has a variety of pharmacological effects. It is a plant-derived quaternary isoquinoline alkaloid with a low water solubility that may be used in the treatment of conditions such as hypercholesterolemia. However, the therapeutic use of BBR has been compromised because of its hydrophobic characteristics, in addition to its low stability and poor bioavailability. To overcome these drawbacks of BBR's oral bioavailability, technologies like liposomal delivery systems have been developed to ensure enhanced absorption. But conventional liposomes have low physical and chemical stability due to delicate liposomal membranes, peroxidation and rapid clearance from the bloodstream. Surface modification of liposomes could be a solution and creating a liposome with plant-based fibers as surface material will provide enhanced stability, aqueous solubility and protection against degradation. Consequently, the aim of this study is to create and describe a Fiber Interlaced Liposome™ (FIL) as a vehicle for an enhanced bioavailability platform for BBR and other biomolecules. This optimised FIL-BBR formulation was analysed for its structural and surface morphological characteristics by using FTIR, SEM, TEM, XRD, zeta potential and DSC. Encapsulation efficiency, stability, and sustained release studies were done using an in vitro digestion model with simulated gastric and intestinal fluids. FIL formulation showed a sustained release of BBR at 59.03 % as compared to the unformulated control (46.73 %) after 8 h of dialysis. Furthermore, the FIL-BBR demonstrated enhanced stability in the simulated gastric fluid (SGF) in addition to a more sustained release in the simulated intestinal fluid (SIF). The efficacy of FIL-BBR were further anlaysed by an in vivo bioavailability study using male Wistar rats and it demonstrated a 3.37 -fold higher relative oral bioavailability compared to the unformulated BBR. The AUC 0-t for BBR in FIL-BBR was 1.38 ng.h/mL, significantly greater than the unformulated BBR (0.041 ng.h/mL). Similarly, the Cmax for BBR in FIL-BBR (50.98 ng/mL) was discovered to be far greater than unformulated BBR (15.54 ng/mL) after the oral administration. These findings imply that fiber based liposomal encapsulation improves the stability and slows down BBR release, which could be advantageous for applications requiring a higher bioavailability and a more sustained release.

Berberine-loaded liposomes for oral delivery: Preparation, physicochemical characterization and in-vivo evaluation in an endogenous hyperlipidemic animal model

Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes

Spray-dried Solid Lipid Nanoparticles for Enhancing Berberine Bioavailability via Oral Administration

Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice.

PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency.

Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.

Preparation, characterization, in vitro and in vivo studies of liposomal berberine using novel natural fiber Interlaced liposomal technology

Optimization of Hyaluronate-Based Liposomes to Augment the Oral Delivery and the Bioavailability of Berberine

Berberine-loaded Solid Proliposomes Prepared Using Solution Enhanced Dispersion by Supercritical CO2: Sustained Release and Bioavailability Enhancement

Membrane Composition Allows the Optimization of Berberine Encapsulation in Liposomes

Preparation, Pharmacokinetics and Tumour-Suppressive Activity of Berberine Liposomes

Development of Natural Polysaccharide–Based Nanoparticles of Berberine to Enhance Oral Bioavailability: Formulation, Optimization, Ex Vivo, and In Vivo Assessment

Design, Synthesis, and Cholesterol-Lowering Efficacy for Prodrugs of Berberrubine.

Berberine: A Perspective Compound in the Development of New Medicines

Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells

Structural modifications of berberine and the lipid-regulating effects of its derivatives

Berberine Hydrochloride-loaded Liposomes Gel: Preparation, Characterization and Antioxidant Activity

Chitosan-coated Nano-Liposomes for the Oral Delivery of Berberine Hydrochloride.

Preparation, physicochemical characterization, and bioactivity evaluation of berberine-entrapped albumin nanoparticles

Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E‐NTPDase in acute hyperlipidemia

Berberine-Loaded Bovine Serum Albumin Nanoparticles: Fabrication, Characterization, and Drug Release Evaluation